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BACKGROUND: Although radiation resistance is a primary issue in radiation therapy, attempts to find predictors of radia-
tion resistance have met with little success. The authors therefore aimed to determine predictors for radiation resistance
to improve the prognosis of head and neck squamous cell carcinoma (HNSCC). METHODS: HNSCC cell lines, SCC15,
SCC25, and QLL1, irradiated with an acute dose of 4 grays (Gy) (RR-4), a cumulative dose of 60 Gy (RR-60), and a
booster dose of 4 Gy over 60 Gy (RR-60 þ 4), were used with nonirradiated cell lines. Those were used in cDNA
microarray, proteomics, Western blotting, and immunofluorescence, respectively. One hundred five HNSCC tissue
samples with radiation resistance were analyzed by immunohistochemistry. RESULTS: Western blot analysis of RR-60
cell lines was identical to the data of Nm23-H1 overexpression by cDNA array and proteomic screening. Immunofluo-
rescence demonstrated significant nuclear translocation of Nm23-H1 in RR-4 and RR-60 cell lines, and less but still
intense nuclear shuttling in RR-60 þ 4. Similarly, Nm23-H1 nuclear localization was observed in 20% (21 of 105) of tis-
sue samples. Univariate analysis demonstrated that Nm23-H1 nuclear localization was strongly associated with overall
and recurrence-free survival. Multivariate stepwise Cox regression analysis showed that Nm23-H1 nuclear localization
(odds ratio [OR], 7.48) and N stage (OR, 2.13) were associated with overall survival, and Nm23-H1 nuclear localization
(OR, 3.02), T stage (OR, 1.43), and insufficient tumor margin (OR, 3.27) were associated with recurrence-free survival.
CONCLUSIONS: Overexpression of Nm23-H1, specifically its nuclear translocation, may be a powerful predictor of
radiation resistance in HNSCC. Cancer 2011;117:1864–73. VC 2010 American Cancer Society.
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Radiation resistance is clinically presented as locoregional failure and a serious problem for patients with advanced
head and neck squamous cell carcinoma (HNSCC). Radiation resistance is responsible in part for 5-year survival rates
below 50% of patients with HNSCC.1 Many attempts have been made to enhance the effectiveness of radiation therapy,
including altered fractional schemes, incorporation of chemotherapy, and molecular targeted therapy. However, despite
the development of antiepithelial growth factor receptor immunotherapy, small molecule kinase inhibitors, and adenovi-
ral vectors to restore p53 or re-express p16,2 surgery and radiotherapy remain the preferred treatments for primary
HNSCC.
Despite vigorous trials to discover biomarkers that predict radiation resistance, there have been few surrogate target
markers, probably not only because the majority of candidates have depended on the exiting methods, but also because
they have not been validated in clinical practice. However, biomarkers for the prediction of radiation resistance are
urgently needed to improve disease-free and overall survival of patients with advanced cancers, including HNSCC. Cellu-
lar radiosensitivity is the result of a combinatorial process comprising a wide variety of signaling and effector molecules.
For instance, effects of epithelial growth factor receptor function on radiosensitivity have been suggested, but the role of
epithelial growth factor receptor in radiosensitivity remains controversial.3-5 In addition, Bcl-2 overexpression and p53
mutation were also associated with radiation resistance in HNSCC.6 PI3K activation, as assessed by Akt phosphorylation,
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or overexpression of hypoxia-inducible factors (eg, HIF1a
and carbonic anhydrase 9) may predict radiation resistance
in tumors showing locoregional failure.7,8 Excision repair
cross-complementation group 1 has also been demonstrated
to predict poor survival,9 and hedgehog activation has been
reported to contribute to chemoradiation resistance in
patients with esophageal cancer with radiation resistance.10
We focused on Nm23-H1 as a biological predictor of radia-
tion resistance based on both cDNA array and proteomics
in the present study. Nm23-H1 is a ubiquitously distrib-
uted nuclear diphosphate kinase that catalyzes the phospho-
rylation of nucleoside diphosphates.11 During tumor
metastasis, Nm23-H1 may inhibit motility in response to
serum and platelet-derived growth factors,12 reduce ERK
activation in response to signaling,13,14 and disassemble the
cytoskeleton.15,16 In the present study, we established radia-
tion-resistant cell lines with cumulative irradiation dosages
identical to the amounts administered in radiotherapy for
patients with HNSCC, and retrospectively analyzed tissue
samples with radiation resistance fromHNSCC patients. In
addition, the biological properties of Nm23-H1 were
assessed to characterize radiation resistance in the event of
Nm23-H1 nuclear localization.
MATERIALS AND METHODS
Generation of Radiation-Resistant Cell Lines
HNSCC cell lines, SCC15, SCC25, and QLL1, were cul-
tured in minimum essential media (GIBCO-BRL, Gai-
thersburg, Md) supplemented with 10% fetal bovine
serum (FBS; GIBCO-BRL), 1% penicillin, and 1% strep-
tomycin. Renal cell carcinoma cell line, caki-1, used for
the acute 4 gray (Gy) dose irradiation (RR-4) test, was
maintained in RPMI1640 (GIBCO-BRL) with 10% FBS
and 1% antibiotics. All cell lines were maintained at 37C
in a humidified atmosphere of 5% CO2.
Cells initially treated with 2 Gy radiation were
grown to 80% confluence after seeding into another flask,
and aliquots accumulated a dosage of 60 Gy after 30 repe-
titions. Those cells were characterized as radiation resist-
ant to the cumulative dose of 60 Gy (RR-60), with
subsequent radiation of 4 Gy (RR-60þ 4).
cDNA Array
All procedures from RNA extraction to cDNAmicroarray
data analysis were done as previously described.17
The only difference between our study and previous




Both RR-60 and nonirradiated cells were directly
homogenized with a motor-driven homogenizer (Power-
Gen125, Fisher Scientific, Pittsburgh, Pa) in 2-dimen-
sional (2D) gel electrophoresis lysis solution composed of
7 M urea, 2 M thiourea, 4% (wt/vol) 3-([3-cholamido-
propyl] dimethylammonio)-1-propanesulfonate, 1% (wt/
vol) dithiothreitol, 2% (vol/vol) Pharmalyte, and 1 mM
benzamidine. Proteins were extracted by vortexing for 1
hour and centrifugation at 15,000  g for 1 hr at 15C.
Insoluble materials were discarded, and the soluble frac-
tions were saved for 2D gel electrophoresis. Protein con-
centration was measured by Bradford assay.
2-DE and image analysis
Briefly, 200 lg of protein extract was separated by
isoelectric focusing using an immobilized pH gradient
strip with a nonlinear pH gradient of 4 to 10 (Genomine,
Kyungbuk, Korea) for the first dimension, and then so-
dium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE; 26  20 cm format) for the second dimen-
sion by molecular weight. Proteins were detected by alka-
line silver staining.
Quantitative analysis of digitized images was carried
out using PDQuest software (version 7.0, BioRad, Hercu-
les, Calif) according to the manufacturer’s protocols.
Quantity of each spot was normalized by total valid spot
intensity.
Protein profile analysis and identification
by mass spectrometry
Clustering of samples and profiling of the protein
expression were performed as described previously.18 For
protein identification, a matrix-assisted laser desorption
ionization time of flight (MALDI-TOF) mass spectrome-
ter was used as previously described.18 The obtained
amino acid sequence was identified by a homology search
in a BLAST search using the ExPASy Molecular Biology
Server (www.expasy.ch).
Western Blot Analysis
To clarify the nuclear shuttling of Nm23-H1, NE-PER
Nuclear and Cytoplasm Extraction Reagents (Pierce Bio-
technology, Rockford, Ill) were used to separate cytoplas-
mic and nuclear extracts. Equal amounts of cell extracts
were subjected to SDS-PAGE and transferred to a nitro-
cellulose membrane (Bio-Rad). Anti–Nm23-H1 anti-
body (1:500 dilution, Abcam, Cambridge, UK) and
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antiaurora kinase A (AURKA) antibody (1:500 dilution,
Abcam) were used as primary antibodies, and antiglyceral-
dehyde-3-phosphate dehydrogenase (1:500 dilution,
GAPDH; Santa Cruz Biotechnology, Santa Cruz, CA)
was used as the internal control. Next, membranes were
washed 3 with phosphate-buffered saline (PBS)-Tween,
and incubated for an additional 1 hour with horseradish
peroxidase-linked secondary antibody diluted in PBS-
Tween with 5% skimmed milk. Donkey polyclonal anti-
bodies against Nm23-H1 and AURKA, and rabbit poly-
clonal antibodies against GAPDH (1:10,000 dilution,
Zymed Laboratories, San Francisco, Calif) were used as
secondary antibodies.
Immunofluorescence
SCC15, SCC25, QLL1, and caki-1 cells seeded on slides
were fixed with precooled methanol at 20C for 10
minutes. Cells were incubated with anti–Nm23-H1 (dilu-
tion, 1:100 in PBS-Tween) and then incubated with Alexa
Fluor 594 secondary antibody (dilution, 1:250; Molecular
Probes, Eugene, Ore and Carlsbad, Calif). The slides were
washed 3 with PBS and mounted with ProLong Gold
Antifade Reagent (Molecular Probes, P36930, Carlsbad,
Calif). Cells were observed by fluorescent inverted micros-
copy (Olympus, Tokyo, Japan, IX71 equipped with DP71
camera). Scattergrams were used for quantification of nu-
clear fractionated frequencies of Nm23-H1. We analyzed
all images using TissueQuest software (TissueGnostics,
Vienna, Austria) to measure the total cell number from the
DAPI images. Cells were plotted according to their Alexa
Fluor 594 intensity versus their DAPI intensity on the scat-
tergrams. We isolated nonspecifically stained structures and
large objects from the image.
Patients and Clinical Findings
We found a total of 105 patients who were eligible for this
study from patient records of the Yonsei University
Health System. All patients had HNSCC (primary tumor
staging: T0, 9.5%; T1, 33.3%; T2, 25.7%; T3, 20.0%;
T4, 11.4%; and regional lymph node staging: N0,
61.0%; N2, 31.4%), and they had been treated with post-
operative 3-dimensional (3D) conformal radiotherapy for
the past 10 years (mean age  standard deviation, 58.2 
11.7 years; male, n ¼ 81 [77.1%]). Mean overall survival
time was 696.3 months (median, 565.5 months). Mean
recurrence-free survival was 569.1 months (median,
426.0 months). All patients provided written informed
consent, and the study was approved by the Research
Ethics Board of Yonsei University Health System.
All patients underwent computed tomography (CT)
simulation (Picker PQ5000 CT scanner, Phillips Medical
Systems, Andover, Mass) with 5 mm thick slice cuts. Intra-
venous contrast agents were used in all patients. Structures
were manually contoured onto the CT scan slices following
the recommendations of the International Commission on
Radiation Units andMeasurements Report 50.
All patients received 3D conformal radiotherapy with
single daily fractions of 2.0 Gy, 5 days per week. The
planned total dose was 60 to 70.0 Gy over 6 to 7 weeks.
The radiation treatment areas included the gross primary
tumor as well as the regional neck nodes. Radiotherapy was
performed with 4MV photon beams from a linear accelera-
tor (CLINAC 600C, Varian Medical Systems, Palo Alto,
Calif). Field reduction at 44 or 45 Gy was completed to
exclude the spinal cord from the large fields. The remaining
dose was delivered to smaller lateral or oblique fields,
including only the primary tumor and clinically or radio-
graphically detectable nodes with a margin of 1 cm. Elec-
tron beams of suitable energy were used to boost the
primary tumor site as well as grossly involved lymph nodes.
Immunohistochemistry
The 4 lm tissue sections were placed on silane-coated slides,
deparaffinized, immersed in PBS containing 0.3% (vol/vol)
hydrogen peroxide, and then processed in a microwave
oven (in 10 mM sodium citrate buffer, pH 6.5, for 15
minutes at 700W). After blocking with 1% (wt/vol) bovine
serum albumin in PBS containing 0.05% (vol/vol) Tween-
20 for 30 minutes, the sections were incubated with biotin-
labeled rabbit anti–Nm23-H1 polyclonal antibodies (dilu-
tion, 1:2000; Abcam) and with biotin-labeled rabbit anti-
AURKA polyclonal antibodies (dilution, 1:400; Abcam) at
4C for 16 hours, respectively. Biotinylation of the antibod-
ies was performed with an antibody biotin-labeling kit
(Envision, Dako, Glustrup, Denmark). Streptavidin-conju-
gated peroxidase was used as a secondary antibody
(1:10,000). Normal goat serum and subtype-matched nor-
mal mouse immunoglobulin G were used as negative con-
trols. The final reaction product was observed by adding
0.03% (wt/vol) of 3,30-diaminobenzidine tetrachloride for
5 to 20 minutes. Carcinomas were semiquantified using a
2-tier system (0, negative staining; 1, weakly focal positive
<50%; 2, strong positive>50%) which included immuno-
localization of cytoplasm and/or nucleoplasm.
Statistical Analysis
Patients were categorized according to Nm23-H1 expres-
sion and localization. Time to recurrence was measured
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from the date of diagnosis to the date of the first local or
distant metastasis or to the last follow-up. Patients who
died before disease recurrence were considered censored at
the date of death. Patients who experienced local recur-
rence as the first recurrence were considered censored at
the date of local recurrence. Times to local and distant re-
currence were estimated by Kaplan-Meier analysis, and
comparisons between groups were made with log-rank
statistics. Cox proportional hazards models were used to
determine the association between expression and nuclear
localization of Nm23H1 and the risk of radiation resist-
ance as assessed by local recurrence. Each model contained
terms for Nm23-H1 cytoplasmic expression, Nm23-H1
nuclear localization, age at diagnosis, tumor size, tumor
type, histological grade, T stage, N stage, M stage, and
incomplete margin. P<.05 was considered significant.
Statistical analyses were performed using SAS software
(SAS, Cary, NC).
RESULTS
Screening of Radiation Resistance-Related
Genes by cDNA Array and Proteomics
A total of 533 genes were differentially expressed in the
cDNA array; 265 genes were up-regulated, and 268 genes
were down-regulated in RR-60 cell lines compared with
nonirradiated cells. One-way hierarchical clustering showed
both up-regulated and down-regulated genes (Fig. 1A).
Fifty-seven proteins (P < .05) were screened by
MALDI-TOF. In analysis of the distance map tree, the
distance between nonirradiated and irradiated cell lines of
RR-60 (SCC15, SCC25, and QLL1) was significantly
great (Fig. 1B).
Figure 1. Screening of radiation resistance predictors by cDNA array and proteomics using 3 different head and neck squamous
cell carcinoma cell lines, SCC15, SCC25, and QLL1, is shown. (A) Hierarchical clustering of cDNA array is shown. The clustering of
SCC15 differed from those of SCC25 and QLL1. (B) Distance map tree represents relative distances between nonirradiated cells
and RR-60 cells from a total of 57 spots (P<.05). (C) Overexpression of Nm23-H1 is observed in both cDNA array and proteomics
results.
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In cDNA array data, DNA repair gene (RFC4), cell
cycle-related gene (CCND1), or signal transduction
related genes (FZD5, CTNNA1) were significantly altered
with >2-fold expression. In addition, cell death or senes-
cence related genes (ie, AATF, TNFRSF11B, DDX60L, or
MAPK6) were significantly related. In proteomics data,
most proteins related to cell cycle-related proliferation
(EIF2S2, PA2G4, MET, MCM4) or DNA replication
(WDR77) were up-regulated, whereas GSTM3 was
down-regulated. Notably, Nm23-H1 was the only over-
lapping gene product that was detected in both cDNA
array and proteomics (Fig. 1C).
Validation of Nm23-H1 Detected by cDNA
Array and Proteomics
Both cDNA array and proteomics results showed Nm23-
H1 as the strongest predictor of radiation resistance. The
Nm23-H1 spot significantly increased in RR-60 SCC15
and SCC25, but not in QLL1. Relative intensities repre-
sent the spot densities on the 2D gel. Nearly a 2-fold
higher density was observed in RR-60 SCC15 and
SCC25 (Fig. 2A). The immunoblotting results revealed
that Nm23-H1 was similarly overexpressed as in the
proteomics results but down-regulated in QLL1 cells
(Fig. 2B).
In Vitro Nuclear Translocation of Nm23-H1 by
Indirect Immunofluorescence
Immunofluorescence demonstrated that Nm23-H1 is
generally localized in the cytoplasm in nonirradiated
HNSCC cell lines. However, HNSCC cells that received
a 4 Gy dose of fractionated radiation (RR-4) demon-
strated nuclear localization of Nm23-H1. Nm23-H1 was
rarely observed in the nuclei of HNSCC and caki-1 cells
that were not irradiated. Caki-1 cells showed nuclear
localization of Nm23-H1 in dot patterns after a 4 Gy dose
of irradiation. Both RR-4 and RR-60 þ 4 demonstrated
fewer nuclear signals than RR-60, but were intensively
stained (Fig. 3A). Nuclear fluorescent signals were quanti-
fied by scattergram. The proportion of Nm23-H1 nuclear
fluorescent signals was increased in RR-60 when com-
pared with nonirradiated cell lines (Fig. 3B). After nuclei/
cytoplasm fractionation, Nm23-H1 signal was elevated
after a single dose of 4 Gy irradiation in nonirradiated
cells. However, RR-60 cells after a 4 Gy booster dose of
irradiation did not induce overexpression of Nm23-H1.
AURKA expression showed a similar pattern with Nm23-
H1. Nm23-H1 expression level in RR-60 of QLL1 was
the same with Western blotting, as shown in Figure 2B.
For this reason, the relationship between AURKA
and Nm23-H1 in RR-60 cells of QLL1 was quite
different from other cell lines. The relative intensity of the
right panel represents the quantity of Nm23-H1
and AURKA in nucleus after GAPDH normalization
(Fig. 3C).
Immunohistochemistry of Nm23-H1
and AURKA in Clinical Samples With
Radiation Resistance
The most common finding of Nm23-H1 in HNSCC
cells was intense staining, especially of tumor nests, in
contrast to no Nm23-H1 staining in normal squamous
epithelium (Fig. 4A). After the analysis of 105 tissue sam-
ples, only cytoplasmic Nm23-H1 expression was detected
in 94 (89.52%) samples. Additional nuclear expression
was detected in 21 (20%) samples, with 5 samples show-
ing predominantly nuclear localization. Nm23-H1 distri-
bution was accentuated along the tumor margin (Fig.
4B). Diffusely infiltrative cancer cells accompanied by a
desmoplastic stromal reaction showed remarkably strong
nuclear staining compared with relatively weak staining in
the epicenters of tumor nests (Fig. 4C). A patchlike distri-
bution of Nm23-H1 was apparent along the invasive
front of the tumor (Fig. 4D). Nm23-H1 was diffusely
localized within the nuclei of certain radiation-resistant
tissues (Fig. 4E) in addition to a typical cytoplasmic
expression (Fig. 4F). AURKA showed nuclear expression
in all cancer cells, more intensely in invasive cells, in par-
ticular (Fig. 4G). All with Nm23-H1 nuclear expression
demonstrated AURKA nuclear coexpression.
Figure 2. Validation of Nm23-H1 is shown. (A) Proteomics
spots were identified as Nm23-H1. Irradiated SCC15 and
SCC25 cell lines showed increased spot density. (B) In West-
ern blotting, SCC15 and SCC25 cells showed high levels of
Nm23-H1 expression in RR-60 cells, whereas the expression
was low in QLL1 cells after glyceraldehyde-3-phosphate de-
hydrogenase (GAPDH) normalization.
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Association of Nm23-H1 Expression With
Overall or Recurrence-Free Survival
Kaplan-Meier analysis demonstrated a significant associa-
tion between cytoplasmic/nuclear expression of Nm23-H1
and overall/recurrence-free survival (Fig. 5). Analysis of
overall and recurrence-free survival using the Cox propor-
tional hazard model is displayed in Tables 1 and 2, respec-
tively. Nuclear localization and cytoplasmic expression of
Nm23-H1 as well as cancer T stage were strongly associated
with overall survival in the univariate model, whereas
Nm23-H1 nuclear localization (OR, 7.48) and N stage
(OR, 2.13) were significant factors in the multivariate Cox
hazardmodel (Table 1). In terms of recurrence-free survival,
cytoplasmic and nuclear expressions of Nm23-H1 as well as
insufficient tumor margins were significant in univariate
analysis, and Nm23-H1 nuclear localization (OR, 2.38)
and indeterminate margin (OR, 3.81) were confirmed by
multivariate stepwise Cox regression analysis (Table 2).
DISCUSSION
Although many have tried to uncover biomarkers that
predict radiation resistance in HNSCC, only Akt phos-
phorylation, overexpression of HIF1a and carbonic anhy-
drase 9,7,8 and excision repair cross-complementation
group 19 were found. Those studies were only involved in
immunochemical analysis of tissues from patients with
locoregional failure, which have limitation in apply for di-
agnosis. To find more reliable markers for radiation resist-
ance, we established RR-60 cell lines by exposing cells to a
cumulative dose of 60 Gy and compared themwith nonir-
radiated cell lines using both preliminary transcriptomics
and proteomics screening. The 60 Gy dose of irradiation
Figure 3. Nm23-H1 nuclear translocation in radiation-treated cell lines is shown. Nm23-H1 translocated to the nucleus is shown in head
and neck cancer cell lines, SCC15, SCC25, and QLL1,with a 4 Gy (humanmedian lethal dose) radiation treatment in nonirradiated cells. (A)
Each panel indicates the localization and intensity of Nm23-H1. The first panel shows nonirradiated cells. Cells in the next panel were
treated with a single 4 Gy dose of radiation. The third panel displays RR-60 cell lines, and the last panel indicates a radiation-resistant cell
line (treated with a total dose of 60 Gy) after a booster dose of 4 Gy. Notice the nuclear speckled pattern in the caki-1 cell line after a 4 Gy
dose of irradiation. (B) Quantitative analysis of immunofluorescence staining of Nm23-H1 is shown. Each scattergram represents the nu-
cleoplasm intensity in SCC15 cell line in a radiation dose-dependent manner. (C) The expression quantity of Nm23-H1 and aurora kinase A
(AURKA) in the nucleoplasm was estimated byWestern blotting, and the highest expression was observed in RR-60 cells. The right panel
represents the relative intensity of Nm23-H1 and AURKA after glyceraldehyde-3-phosphate dehydrogenase (GAPDH) normalization.
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Figure 5. Kaplan-Meier analysis of Nm23-H1 expression and survival is shown: (A) association between Nm23-H1 cytoplasmic expression
and overall survival; (B) association between Nm23-H1 nuclear expression and overall survival; (C) association between Nm23-H1 cyto-
plasmic expression and recurrence-free survival; (D) association between Nm23-H1 nuclear expression and recurrence-free survival.
Figure 4. Immunohistochemistry of Nm23-H1 in head and neck squamous cell carcinoma archival tissue samples from patients who pre-
sented with locoregional failure after therapeutic radiotherapy is shown. (A) Typical expression of Nm23-H1 along the basal layers and
invasive squamous cell carcinoma (SCC) are shown. Notice the negative staining in the normal squamous epithelium (NL). (B) Nm23-H1
revealed strong immunoreactivity along the margin of invasive tumor nests (arrows). (C) Remarkable nuclear staining in infiltrative tumor
nests within the desmoplastic stromal reaction is shown (arrows). Note the relatively weak staining in the epicenters of SCC nests (arrow-
heads). (D) A patch-like distribution of Nm23-H1 nuclear staining in invasive fronts of the tumor is shown. (E) Diffuse nuclear localization
of Nm23-H1 is shown. (F) Cytoplasmic staining of Nm23-H1 with no obvious nuclear localization identified is seen in most tumor nests.
(G) Aurora kinase A showed nuclear expression in all cancer cells, more intensely in the invasive cells in particular.
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is widely used in HNSCC radiotherapy as well as investi-
gation on tissue samples.
There were several studies using cDNA array or pro-
teomics to discover markers for radiation resistance in
HNSCC.19,20 One study found that the expression of 25
genes were altered by radiation, and 11 of them were vali-
dated in oral squamous cell carcinoma cell lines after radia-
tion up to 8 Gy, such as ICAM2, TIMP3, PLAGL1, and
FGFR3.20 In another study, 48 genes were significantly
altered in myeloid cell lines (ML-1) by radiation that were
primarily apoptosis-related genes such as Fas, Ciap1, Bak,
and Bcl-XL.21 In a study using proteomics, head and neck
cancer cell lines that were exposed to a 4 Gy dose of radia-
tion showed differential expression of proteins as follows:
heat shock protein (hsp) 27, peroxiredoxin (Prx) II, and glu-
tathione S-transferase pi (GSTP).22 Althoughmany putative
radiation resistance-related genes or proteins have been
found, the demand for a reliable radiation resistance marker
remained. In our study, we used both cDNA array and pro-
teomics for screening, which may increase the reliability of
radiation resistance candidates by being double checked, in
RR-60 and nonirradiated cell lines. Nm23-H1 was signifi-
cantly increased in RR-60 cell lines and nonirradiated cells
exposed to 4 Gy of booster irradiation. Also, the overexpres-
sion of Nm23-H1 in nucleus was found in RR-60 cell lines.
It has been reported that Nm23-H1 is usually located in
cytoplasm, not nucleus. Therefore, we postulated that
Nm23-H1 would have another function on radiation resist-
ance by nuclear translocation. To determine how cells
respond to radiation, especially in Nm23-H1 expression in
nucleus, we exposed each cell line to 4 Gy booster radiation.
The overexpression of Nm23-H1 in nucleus was observed
in the nonirradiated cell lines exposed to 4 Gy of booster
irradiation. However, there was no significant increase of
Nm23-H1 in nucleus of RR-60 cell lines. RR-60 cells may
have already acquired Nm23-H1 overexpression in nucleus
by repeated radiation. The assumption can be supported by
the report that Nm23-H1 may play a role in DNA damage
repair or the induction of DNA synthesis.23,24 Nm23-H1
mediated DNA repair maintains genomic stability after irra-
diation or UV irradiation.23,24 DNA repair from irradiation
targeted to double-stranded DNA of cancer cells may lead
to survival of cancer.
In addition, we validated predictor (Nm23-H1)
expression in a large number of tissues from HNSCC
patients with locoregional failure. As we mentioned above,
Nm23-H1 is normally found in cytoplasm, and its nuclear
localization has seldom been reported. However, we
observed nuclear localization of Nm23-H1 in HNSCC.
The most common finding of Nm23-H1 was cytoplasmic
staining, with accentuation along the tumor margins or
invasive fronts, but nuclear and cytoplasmic coexpression
was also detected in 20% of a total samples. We noticed
accentuation along the tumor margins or invasive fronts of
Nm23-H1, which indicate that Nm23-H1 is related to
with invasive potential and poor prognostic factor. In addi-
tion to distribution patterns, multivariate Cox hazardmodel
also showed nuclear localization as a significant poor prog-
nostic factor. Our finding is consistent with another study
reporting Nm23-H1 nuclear localization as a progressive
marker in breast cancer.25 Both nuclear and cytoplasmic
staining were seen in 24.3% of lymph node-positive infil-
trating ductal carcinoma (IDC) and 18.9% of matched
lymph node metastasis cases, compared with 4.9% staining
in lymph node-negative IDC.25
The functional mechanism of Nm23-H1 nuclear
translocation as a poor prognostic factor has not been clari-
fied. With specific regard to the functional mechanism, Fan
Table 1. Univariate and Multivariate Overall Survival Analyses
Using the Cox Proportional Hazard Model
Characteristic Univariate Multivariate
P HR P HR
Age .5572 0.99 .1486 1.07
Tumor margin .0695 2.16 .3265 3.30
Tumor size .1333 1.14 .8746 1.07
Nm23-Cyto .0064a 2.54 .2340 0.54
Nm23-Nuc <.0001a 7.54 <.0001a 7.48
T stage .0366a 1.35 .8138 1.14
N stage .1925 1.25 .0254a 2.13
HR indicates hazard ratio; Nm23-Cyto, cytoplasmic localization of Nm23-
H1; Nm23-Nuc, nuclear localization of Nm23-H1.
a Statistically significant.
Table 2. Univariate and Multivariate Recurrence-Free Survival
Analyses Using the Cox Proportional Hazard Model
Characteristic Univariate Multivariate
P HR P HR
Age .4925 0.99 .4221 0.99
Tumor margin .0113a 3.17 .0037a 3.81
Tumor size .8764 0.97 .8320 0.96
Nm23-Cyto .0009a 1.78 .1617 1.39
Nm23-Nuc .0001a 2.40 .0138a 2.38
T stage .1315 1.47 .0812 1.61
N stage .8953 0.97 .8331 0.96
HR indicates hazard ratio; Nm23-Cyto, cytoplasmic localization of Nm23-
H1; Nm23-Nuc, nuclear localization of Nm23-H1.
a Statistically significant.
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et al mentioned that granzyme A secreted from cytotoxic T
cells can induce the single-strand DNA nick of target cells
via the nuclear translocation of Nm23-H1.26 In another
report, Nm23-H1 interacts with AURKA, which might
have a function in radioresistance.27,28 AURKA is a centro-
some-associated kinase, and its overexpression in rodent
and human cancer cells causes improper centrosome dupli-
cation, aneuploidy, and cellular transformation.27 Accumu-
lation of Nm23-H1 on the centrosome coincides with the
enrichment of AURKA at the centrosome and with
increased AURKA activity in the beginning of mitosis
through a microtubule-independent mechanism.28 On the
basis of references and our results, Nm23-H1 may play a
role in DNA damage repair or the induction of DNA syn-
thesis together with AURKA. AURKA showed a coexpres-
sion pattern with Nm23-H1 in SCC15 and SCC25, but
not inQLL1. AURKA showed nuclear expression in all can-
cer cell lines, and its expression pattern overlapped with
Nm23-H1 in most cases. According to coexpression with
AURKA in the event of nuclear translocation of Nm23-
H1, we suggest another putative pathway by which Nm23-
H1 directly interacts with AURKA in head and neck cancer
undergoing radiation resistance.
Nm23-H1 is a reliable candidate for radiation resist-
ance prediction in HNSCC. There has not been any
report on Nm23-H1 overexpression in nucleus and nu-
clear translocation in other cancers such as thyroid cancer,
ovarian cancer, T-cell lymphoma, and neuroblastomas af-
ter irradiation.29-32 Also, there are several reports that
Nm23-H1 expression is associated with a favorable prog-
nosis or shows a lack of association with head and neck
cancer.33,34 Thus, Nm23-H1 is thought to have tissue-
specific roles with different regulatory mechanisms, and
its overexpression may be specific to HNSCC.
In conclusion, nuclear translocation of Nm23-H1
may be a meaningful and strong predictor of radiation re-
sistance in patients with HNSCC.
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